{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:36:06Z","timestamp":1769085366064,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"China youth clinical research fund","award":["2017-CCA-VG-003"],"award-info":[{"award-number":["2017-CCA-VG-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10557-020-06956-4","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T10:03:00Z","timestamp":1583402580000},"page":"179-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1007","volume":"34","author":[{"given":"Ziwei","family":"Xi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"issue":"40","key":"6956_CR1","first-page":"87","volume":"2019","author":"FJ Neumann","year":"2018","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J. 2018;2019(40):87\u2013165.","journal-title":"Eur Heart J"},{"issue":"39","key":"6956_CR2","first-page":"213","volume":"2018","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;2018(39):213\u201360.","journal-title":"Eur Heart J"},{"key":"6956_CR3","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","volume":"107","author":"PA Gurbel","year":"2003","unstructured":"Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908\u201313.","journal-title":"Circulation"},{"key":"6956_CR4","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2217\/pgs.09.143","volume":"10","author":"KJ Ellis","year":"2009","unstructured":"Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009;10:1799\u2013817.","journal-title":"Pharmacogenomics"},{"key":"6956_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354\u201362.","journal-title":"N Engl J Med"},{"key":"6956_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama. 2009;302:849\u201357.","journal-title":"Jama"},{"key":"6956_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/CIRCGENETICS.114.000669","volume":"7","author":"MJ Sorich","year":"2014","unstructured":"Sorich MJ, Rowland A, McKinnon RA, Wiese MD. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet. 2014;7:895\u2013902.","journal-title":"Circ Cardiovasc Genet"},{"key":"6956_CR8","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Jama. 2010;304:1821\u201330.","journal-title":"Jama"},{"key":"6956_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jjcc.2013.03.006","volume":"62","author":"Z Nagashima","year":"2013","unstructured":"Nagashima Z, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, et al. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. J Cardiol. 2013;62:158\u201364.","journal-title":"J Cardiol"},{"key":"6956_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIR.0b013e3181ee08ed","volume":"122","author":"DR Holmes Jr","year":"2010","unstructured":"Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF\/AHA clopidogrel clinical alert: approaches to the FDA \u201cboxed warning\u201d: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537\u201357.","journal-title":"Circulation"},{"key":"6956_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"6956_CR12","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"6956_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1161\/ATVBAHA.118.311963","volume":"39","author":"MD Klein","year":"2019","unstructured":"Klein MD, Williams AK, Lee CR, Stouffer GA. Clinical utility of CYP2C19 genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2019;39:647\u201352.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6956_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","volume":"11","author":"LH Cavallari","year":"2018","unstructured":"Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11:181\u201391.","journal-title":"JACC Cardiovasc Interv"},{"key":"6956_CR15","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","volume":"60","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"6956_CR16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"6956_CR17","doi-asserted-by":"publisher","unstructured":"Martin J, Williams AK, Klein MD, et al. Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. Genet Med. 2020;22(1):160\u2013169. https:\/\/doi.org\/10.1038\/s41436-019-0611-1.","DOI":"10.1038\/s41436-019-0611-1"},{"key":"6956_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2217\/pgs-2018-0072","volume":"19","author":"MD Klein","year":"2018","unstructured":"Klein MD, Lee CR, Stouffer GA. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. Pharmacogenomics. 2018;19:1039\u201346.","journal-title":"Pharmacogenomics"},{"key":"6956_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12967-018-1469-8","volume":"16","author":"LH Cavallari","year":"2018","unstructured":"Cavallari LH, Franchi F, Rollini F, Been L, Rivas A, Agarwal M, et al. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Transl Med. 2018;16:92.","journal-title":"J Transl Med"},{"key":"6956_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/09537104.2017.1413178","volume":"30","author":"Z Xi","year":"2019","unstructured":"Xi Z, Fang F, Wang J, AlHelal J, Zhou Y, Liu W. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis. Platelets. 2019;30:229\u201340.","journal-title":"Platelets"},{"key":"6956_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94:317\u201323.","journal-title":"Clin Pharmacol Ther"},{"key":"6956_CR22","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.113.001437","volume":"127","author":"RS Kumar","year":"2013","unstructured":"Kumar RS, Douglas PS, Peterson ED, Anstrom KJ, Dai D, Brennan JM, et al. Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423 965 patients in the linked National Cardiovascular Data Registry and centers for Medicare & Medicaid services payer databases. Circulation. 2013;127:1395\u2013403.","journal-title":"Circulation"},{"key":"6956_CR23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ahj.2008.08.031","volume":"157","author":"KH Mak","year":"2009","unstructured":"Mak KH, Bhatt DL, Shao M, Hankey GJ, Easton JD, Fox KA, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J. 2009;157:658\u201365.","journal-title":"Am Heart J"},{"key":"6956_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.gheart.2014.08.001","volume":"9","author":"GN Levine","year":"2014","unstructured":"Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, et al. World heart federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Glob Heart. 2014;9:457\u201367.","journal-title":"Glob Heart"},{"key":"6956_CR25","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1093\/eurheartj\/ehw284","volume":"37","author":"A Sahlen","year":"2016","unstructured":"Sahlen A, Varenhorst C, Lagerqvist B, Renlund H, Omerovic E, Erlinge D, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016;37:3335\u201342.","journal-title":"Eur Heart J"},{"key":"6956_CR26","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320\u20138.","journal-title":"Lancet"},{"key":"6956_CR27","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","volume":"12","author":"D Sibbing","year":"2019","unstructured":"Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12:1521\u201337.","journal-title":"JACC Cardiovasc Interv"},{"key":"6956_CR28","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","volume":"71","author":"FM Notarangelo","year":"2018","unstructured":"Notarangelo FM, Maglietta G, Bevilacqua P, Cereda M, Merlini PA, Villani GQ, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO Trial. J Am Coll Cardiol. 2018;71:1869\u201377.","journal-title":"J Am Coll Cardiol"},{"key":"6956_CR29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","volume":"381","author":"DMF Claassens","year":"2019","unstructured":"Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, AWJ V\u2019t H, Van der Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621\u201331.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06956-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-020-06956-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06956-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:23:29Z","timestamp":1614903809000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-020-06956-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["6956"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-06956-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"5 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution (ethics committee of Beijing Anzhen Hospital, no. 2019006X)) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}